Genetics, transcriptomics, and proteomics of Alzheimer's disease

Journal of Clinical Psychiatry

Volumn 67, Issue 4, 2006, Pages 652-670

  Papassotiropoulos, Andreas ^a,c   Fountoulakis, Michael ^b   Dunckley, Travis ^c,f   Stephan, Dietrich A ^c,f   Reiman, Eric M ^c,d,e,f  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b Academy of Athens Biomedical Research Foundation   (Greece)

^c TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^d BANNER ALZHEIMER S INSTITUTE   (United States)

^e UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^f ARIZONA ALZHEIMER S CONSORTIUM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; PRESENILIN 1; PRESENILIN 2;

ALZHEIMER DISEASE; DATA SYNTHESIS; DISEASE COURSE; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GENETIC RISK; HUMAN; INHERITANCE; LIPID METABOLISM; MEDICAL LITERATURE; OXIDATIVE STRESS; PATHOGENESIS; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEOMICS; REVIEW; TRANSCRIPTOMICS;

EID: 33646812919     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n0418     Document Type: Review

References (233)

1. Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. JAMA 1989;262:2551-2556
2. Gatz M, Pedersen NL, Berg S, et al. Heritability for Alzheimer's disease: the study of dementia in Swedish twins. J Gerontol A Biol Sci Med Sci 1997;52:M117-M125
3. Heston LL, Mastri AR, Anderson VE, et al. Dementia of the Alzheimer type: clinical genetics, natural history, and associated conditions. Arch Gen Psychiatry 1981;38:1085-1090
4. Heyman A, Wilkinson WE, Hurwitz BJ, et al. Alzheimer's disease: genetic aspects and associated clinical disorders. Ann Neurol 1983;14:507-515
5. Breitner JC, Folstein MF. Familial Alzheimer dementia: a prevalent disorder with specific clinical features. Psychol Med 1984;14:63-80
6. Breitner JC, Folstein MF, Murphy EA. Familial aggregation in Alzheimer dementia, 1: a model for the age-dependent expression of an autosomal dominant gene. J Psychiatr Res 1986;20:31-43
7. Huff FJ, Auerbach J, Chakravarti A, et al. Risk of dementia in relatives of patients with Alzheimer's disease. Neurology 1988;38:786-790
8. Fairer LA, O'Sullivan DM, Cupples LA, et al. Assessment of genetic risk for Alzheimer's disease among first-degree relatives. Ann Neurol 1989;25:485-493
9. Korten AE, Jorm AF, Henderson AS, et al. Assessing the risk of Alzheimer's disease in first-degree relatives of Alzheimer's disease cases. Psychol Med 1993;23:915-923
10. Silverman JM, Raiford K, Edland S, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), pt 6: family history assessment: a multicenter study of first-degree relatives of Alzheimer's disease probands and nondemented spouse controls. Neurology 1994;44:1253-1259
11. Silverman JM, Li G, Zaccario ML, et al. Patterns of risk in first-degree relatives of patients with Alzheimer's disease. Arch Gen Psychiatry 1994;51:577-586
12. Heun R, Papassotiropoulos A, Jessen F, et al. A family study of Alzheimer disease and early- and late-onset depression in elderly patients. Arch Gen Psychiatry 2001;58:190-196
13. Roberts SB, MacLean CJ, Neale MC, et al. Replication of linkage studies of complex traits: an examination of variation in location estimates. Am J Hum Genet 1999;65:876-884
14. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997;278:1349-1356
15. Horvath S, Xu X, Laird NM. The family based association test method: strategies for studying general genotype-phenotype associations. Eur J Hum Genet 2001;9:301-306
16. Pritchard JK, Rosenberg NA. Use of unlinked genetic markers to detect population stratification in association studies. Am J Hum Genet 1999;65:220-228
17. Devlin B, Roeder K. Genomic control for association studies. Biometrics 1999;55:997-1004
18. Lohmueller KE, Pearce CL, Pike M, et al. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 2003;33:177-182
19. Breslow JL, Zannis VI, SanGiacomo TR, et al. Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2. J Lipid Res 1982;23:1224-1235
20. Poirier J, Davignon J, Bouthillier D, et al. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993;342:697-699
21. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-1472
22. Osuntokun BO, Sahota A, Ogunniyi AO, et al. Lack of an association between apolipoprotein E epsilon 4 and Alzheimer's disease in elderly Nigerians. Ann Neurol 1995;38:463-465
23. Tang MX, Maestre G, Tsai WY, et al. Relative risk of Alzheimer disease and age-at-onset distributions, based on APOE genotypes among elderly African Americans, Caucasians, and Hispanics in New York City. Am J Hum Genet 1996;58:574-584
24. Corbo RM, Scacchi R. Apolipoprotein E (APOE) allele distribution in the world: is APOE*4 a 'thrifty' allele? Ann Hum Genet 1999;63(pt 4):301-310
25. Poirier J, Delisle MC, Quirion R, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A 1995;92:12260-12264
26. Roses AD. Apolipoprotein E and Alzheimer's disease: a rapidly expanding field with medical and epidemiological consequences. Ann N Y Acad Sci 1996;802:50-57
27. Statement on use of apolipoprotein E testing for Alzheimer disease. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer Disease. JAMA 1995;274:1627-1629
28. McConnell LM, Sanders GD, Owens DK. Evaluation of genetic tests: APOE genotyping for the diagnosis of Alzheimer disease. Genet Test 1999;3:47-53
29. Cupples LA, Farrer LA, Sadovnick AD, et al. Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: the REVEAL study. Genet Med 2004;6:192-196
30. LaRusse S, Roberts JS, Marteau TM, et al. Genetic susceptibility testing versus family history-based risk assessment: impact on perceived risk of Alzheimer disease. Genet Med 2005;7:48-53
31. Guidelines for the molecular genetics predictive test in Huntington's disease. International Huntington Association (IHA) and the World Federation of Neurology (WFN) Research Group on Huntington's Chorea. Neurology 1994;44:1533-1536
32. Panegyres PK, Goldblatt J, Walpole I, et al. Genetic testing for Alzheimer's disease. Med J Aust 2000;172:339-343
33. Papassotiropoulos A, Streffer JR, Tsolaki M, et al. Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. Arch Neurol 2003;60:29-35
34. Crawford FC, Freeman MJ, Schinka JA, et al. A polymorphism in the cystatin C gene is a novel risk factor for late-onset Alzheimer's disease. Neurology 2000;55:763-768
35. Grimaldi LM, Casadei VM, Ferri C, et al. Association of early-onset Alzheimer's disease with an interleukin-1 alpha gene polymorphism. Ann Neurol 2000;47:361-365
36. Nicoll JA, Mrak RE, Graham DI, et al. Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann Neurol 2000;47:365-368
37. Licastro F, Grimaldi LM, Bonafe M, et al. Interleukin-6 gene alleles affect the risk of Alzheimer's disease and levels of the cytokine in blood and brain. Neurobiol Aging 2003;24:921-926
38. Papassotiropoulos A, Bagli M, Jessen F, et al. A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease. Ann Neurol 1999;45:666-668
39. Vollbach H, Heun R, Morris CM, et al. APOA1 polymorphism influences risk for early-onset nonfamiliar AD. Ann Neurol 2005;58:436-441
40. Bertram L, Hiltunen M, Parkinson M, et al. Family-based association between Alzheimer's disease and variants in UBQLN1. N Engl J Med 2005;352:884-894
41. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science 1996;273:1516-1517
42. Xu Q, Jia YB, Zhang BY, et al. Association study of an SNP combination pattern in the dopaminergic pathway in paranoid schizophrenia: a novel strategy for complex disorders. Mol Psychiatry 2004;9:510-521
43. Papassotiropoulos A, Wollmer MA, Tsolaki M, et al. A cluster of cholesterol-related genes confers susceptibility for Alzheimer's disease. J Clin Psychiatry 2005;66:940-947
44. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005;308:385-389
45. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003;160:636-645
46. Reiman EM, Chen K, Alexander GE, et al. Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci U S A 2005;102:8299-8302
47. St George-Hyslop PH, Tanzi RE, Polinsky RJ, et al. The genetic defect causing familial Alzheimer's disease maps on chromosome 21. Science 1987;235:885-890
48. Tanzi RE, Gusella JF, Watkins PC, et al. Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 1987;235:880-884
49. Levy E, Carman MD, Fernandez-Madrid IJ, et al. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 1990;248:1124-1126
50. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991;349:704-706
51. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992;256:184-185
52. Schellenberg GD, Bird TD, Wijsman EM, et al. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science 1992;258:668-671
53. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995;375:754-760
54. Levy-Lahad E, Lahad A, Wijsman EM, et al. Apolipoprotein E genotypes and age of onset in early-onset familial Alzheimer's disease. Ann Neurol 1995;38:678-680
55. Axelman K, Basun H, Lannfelt L. Wide range of disease onset in a family with Alzheimer disease and a His163Tyr mutation in the presenilin-1 gene. Arch Neurol 1998;55:698-702
56. Campion D, Brice A, Hannequin D, et al. A large pedigree with early-onset Alzheimer's disease: clinical, neuropathologic, and genetic characterization. Neurology 1995;45:80-85
57. Ezquerra M, Carnero C, Blesa R, et al. A presenilin 1 mutation (Ser169Pro) associated with early-onset AD and myoclonic seizures. Neurology 1999;52:566-570
58. Janssen JC, Hall M, Fox NC, et al. Alzheimer's disease due to an intronic presenilin-1 (PSEN1 intron 4) mutation: a clinicopathological study. Brain 2000;123 (pt 5):894-907
59. Kennedy AM, Newman SK, Frackowiak RS, et al. Chromosome 14 linked familial Alzheimer's disease: a clinico-pathological study of a single pedigree. Brain 1995;118 (pt 1):185-205
60. Lampe TH, Bird TD, Nochlin D, et al. Phenotype of chromosome 14-linked familial Alzheimer's disease in a large kindred. Ann Neurol 1994;36:368-378
61. Reznik-Wolf H, Treves TA, Davidson M, et al. A novel mutation of presenilin 1 in familial Alzheimer's disease in Israel detected by denaturing gradient gel electrophoresis. Hum Genet 1996;98:700-702
62. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996;2:864-870
63. Marjaux E, Hartmann D, De SB. Presenilins in memory, Alzheimer's disease, and therapy. Neuron 2004;42:189-192
64. Bird TD, Lampe TH, Nemens EJ, et al. Familial Alzheimer's disease in American descendants of the Volga Germans: probable genetic founder effect. Ann Neurol 1988;23:25-31
65. Levy-Lahad E, Wijsman EM, Nemens E, et al. A familial Alzheimer's disease locus on chromosome 1. Science 1995;269:970-973
66. Ho L, Guo Y, Spielman L, et al. Altered expression of a-type but not retype synapsin isoform in the brain of patients at high risk for Alzheimer's disease assessed by DNA microarray technique. Neurosci Lett 2001;298:191-194
67. Colangelo V, Schurr J, Ball MJ, et al. Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling. J Neurosci Res 2002;70:462-473
68. Hata R, Masumura M, Akatsu H, et al. Up-regulation of calcineurin Abeta mRNA in the Alzheimer's disease brain: assessment by cDNA microarray. Biochem Biophys Res Commun 2001;284:310-316
69. Beglopoulos V, Sun X, Saura CA, et al. Reduced beta-amyloid production and increased inflammatory responses in presenilin conditional knock-out mice. J Biol Chem 2004:279:46907-46914
70. Kim JR, Lee SR, Chung HJ, et al. Identification of amyloid beta-peptide responsive genes by cDNA microarray technology: involvement of RTP801 in amyloid beta-peptide toxicity. Exp Mol Med 2003;35:403-411
71. Wu ZL, Ciallella JR, Flood DG, et al. Comparative analysis of cortical gene expression in mouse models of Alzheimer's disease. Neurobiol Aging 2006;27:377-386
72. Kong LN, Zuo PP, Mu L, et al. Gene expression profile of amyloid beta protein-injected mouse model for Alzheimer disease. Acta Pharmacol Sin 2005;26:666-672
73. Mirnics K, Korade Z, Arion D, et al. Presenilin-1-dependent transcriptome changes. J Neurosci 2005;25:1571-1578
74. Chen F, Wollmer MA, Hoemdli F, et al. Role for glyoxalase I in Alzheimer's disease. Proc Natl Acad Sci U S A 2004;101:7687-7692
75. Mufson EJ, Counts SE, Ginsberg SD. Gene expression profiles of cholinergic nucleus basalis neurons in Alzheimer's disease. Neurochem Res 2002;27:1035-1048
76. Ginsberg SD, Hemby SE, Lee VM, et al. Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons. Ann Neurol 2000;48:77-87
77. Dunckley T, Beach TG, Ramsey KE, et al. Gene expression correlates of neurofibrillary tangles in Alzheimer's disease. Neurobiol Aging 2005 Oct 18 [Epub ahead of print]
78. David DC, Hoemdli F, Gotz J. Functional genomics meets neurodegenerative disorders, pt 1: transcriptomic and proteomic technology. Prog Neurobiol 2005;76:153-168
79. Hoerndli F, David DC, Gotz J. Functional genomics meets neurodegenerative disorders, pt 2: application and data integration. Prog Neurobiol 2005;76:169-188
80. Gillardon F, Steinlein P, Burger E, et al. Phosphoproteome and transcriptome analysis of the neuronal response to a CDK5 inhibitor. Proteomics 2005;5:1299-1307
81. Fountoulakis M. Proteomics: current technologies and applications in neurological disorders and toxicology. Amino Acids 2001;21:363-381
82. Fountoulakis M. Two-Dimensional Electrophoresis. Encyclopedia of Separation Science, II/Electrophoresis. London: Academic Press; 2000:1356-1363
83. Fountoulakis M, Takacs B. Enrichment and proteomic analysis of low-abundance bacterial proteins. Methods Enzymol 2002;358:288-306
84. Righetti PG, Castagna A, Herbert B, et al. Prefractionation techniques in proteome analysis. Proteomics 2003;3:1397-1407
85. O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. J Biol Chem 1975;250:4007-4021
86. Klose J. Protein mapping by combined isoelectric focusing and electrophoresis of mouse tissues: a novel approach to testing for induced point mutations in mammals. Humangenetik 1975;26:231-243
87. Lahm HW, Langen H. Mass spectrometry: a tool for the identification of proteins separated by gels. Electrophoresis 2000;21:2105-2114
88. Jiang L, Lindpaintner K, Li HF, et al. Proteomic analysis of the cerebrospinal fluid of patients with schizophrenia. Amino Acids 2003;25:49-57
89. Fountoulakis M. Application of proteomics technologies in the investigation of the brain. Mass Spectrom Rev 2004;23:231-258
90. Cash P. Proteomics in medical microbiology. Electrophoresis 2000;21:1187-1201
91. Rohlff C. Proteomics in molecular medicine: applications in central nervous systems disorders. Electrophoresis 2000;21:1227-1234
92. Cordwell SJ, Nouwens AS, Walsh BJ. Comparative proteomics of bacterial pathogens. Proteomics 2001;1:461-472
93. Simpson RJ, Dorow DS. Cancer proteomics: from signaling networks to tumor markers. Trends Biotechnol 2001;19:S40-S48
94. Hanash S. Disease proteomics. Nature 2003;422:226-232
95. Antonarakis SE. 10 years of genomics, chromosome 21, and Down syndrome. Genomics 1998;51:1-16
96. Cairns NJ. Neuropathology. J Neural Transm Suppl 1999;57:61-74
97. Engidawork E, Lubec G. Protein expression in Down syndrome brain. Amino Acids 2001;21:331-361
98. Cheon MS, Kim SH, Yaspo ML, et al. Protein levels of genes encoded on chromosome 21 in fetal Down syndrome brain: challenging the gene dosage effect hypothesis, pt 1. Amino Acids 2003;24:111-117
99. Liao L, Cheng D, Wang J, et al. Proteomic characterization of postmortem amyloid plaques isolated by laser capture microdissection. J Biol Chem 2004;279:37061-37068
100. Greber S, Lubec G, Cairns N, et al. Decreased levels of synaptosomal associated protein 25 in the brain of patients with Down syndrome and Alzheimer's disease. Electrophoresis 1999;20:928-934
101. Agashe VR, Hartl FU. Roles of molecular chaperones in cytoplasmic protein folding. Semin Cell Dev Biol 2000;11:15-25
102. Ellis RJ. Molecular chaperones ten years. Introduction. Semin Cell Dev Biol 2000;11:1-5
103. Yoo BC, Kim SH, Cairns N, et al. Deranged expression of molecular chaperones in brains of patients with Alzheimer's disease. Biochem Biophys Res Commun 2001;280:249-258
104. Castegna A, Aksenov M, Thongboonkerd V, et al. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain, pt 2: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J Neurochem 2002;82:1524-1532
105. Castegna A, Aksenov M, Aksenova M, et al. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain, pt 1: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med 2002;33:562-571
106. Yoo BC, Vlkolinsky R, Engidawork E, et al. Differential expression of molecular chaperones in brain of patients with Down syndrome. Electrophoresis 2001;22:1233-1241
107. Yoo BC, Cairns N, Fountoulakis M, et al. Synaptosomal proteins, beta-soluble N-ethylmaleimide-sensitive factor attachment protein (beta-SNAP), gamma-SNAP and synaptotagmin 1 in brain of patients with Down syndrome and Alzheimer's disease. Dement Geriatr Cogn Disord 2001;12:219-225
108. Lubec G, Nonaka M, Krapfenbauer K, et al. Expression of the dihydropyrimidinase related protein 2 (DRP-2) in Down syndrome and Alzheimer's disease brain is downregulated at the mRNA and dysregulated at the protein level. J Neural Transm Suppl 1999;57:161-177
109. Butterfield DA, Boyd-Kimball D, Castegna A. Proteomics in Alzheimer's disease: insights into potential mechanisms of neurodegeneration. J Neurochem 2003;86:1313-1327
110. Vlkolinsky R, Cairns N, Fountoulakis M, et al. Decreased brain levels of 2,'3'-cyclic nucleotide-3'-phosphodiesterase in Down syndrome and Alzheimer's disease. Neurobiol Aging 2001;22:547-553
111. Kim SH, Fountoulakis M, Cairns NJ, et al. Human brain nucleoside diphosphate kinase activity is decreased in Alzheimer's disease and Down syndrome. Biochem Biophys Res Commun 2002;296:970-975
112. Cheon MS, Fountoulakis M, Cairns NJ, et al. Decreased protein levels of stathmin in adult brains with Down syndrome and Alzheimer's disease. J Neural Transm Suppl 2001;61:281-288
113. Fountoulakis M, Cairns N, Lubec G. Increased levels of 14-3-3 gamma and epsilon proteins in brain of patients with Alzheimer's disease and Down syndrome. J Neural Transm Suppl 1999;57:323-335
114. Engidawork E, Lubec G. Molecular changes in fetal Down syndrome brain. J Neurochem 2003;84:895-904
115. Soulie C, Nicole A, Delacourte A, et al. Examination of stress-related genes in human temporal versus occipital cortex in the course of neurodegeneration: involvement of 14-3-3 zeta in this dynamic process. Neurosci Lett 2004;365:1-5
116. Gulesserian T, Seidl R, Hardmeier R, et al. Superoxide dismutase SOD1, encoded on chromosome 21, but not SOD2 is overexpressed in brains of patients with Down syndrome. J Investig Med 2001;49:41-46
117. Balcz B, Kirchner L, Cairns N, et al. Increased brain protein levels of carbonyl reductase and alcohol dehydrogenase in Down syndrome and Alzheimer's disease. J Neural Transm Suppl 2001;61:193-201
118. Krapfenbauer K, Engidawork E, Cairns N, et al. Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders. Brain Res 2003;967:152-160
119. Kim SH, Fountoulakis M, Cairns N, et al. Protein levels of human peroxiredoxin subtypes in brains of patients with Alzheimer's disease and Down syndrome. J Neural Transm Suppl 2001;61:223-235
120. Kim H, Lee TH, Park ES, et al. Role of peroxiredoxins in regulating intracellular hydrogen peroxide and hydrogen peroxide-induced apoptosis in thyroid cells. J Biol Chem 2000;275:18266-18270
121. Engidawork E, Gulesserian T, Seidl R, et al. Expression of apoptosis related proteins in brains of patients with Alzheimer's disease. Neurosci Lett 2001;303:79-82
122. Butterfield DA. Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain: a review. Free Radic Res 2002;36:1307-1313
123. Butterfield DA. Proteomics: a new approach to investigate oxidative stress in Alzheimer's disease brain. Brain Res 2004;1000:1-7
124. Lubec G, Krapfenbauer K, Fountoulakis M. Proteomics in brain research: potentials and limitations. Prog Neurobiol 2003;69:193-211
125. Mullan M, Crawford F, Axelman K, et al. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet 1992;1:345-347
126. Wakutani Y, Watanabe K, Adachi Y, et al. Novel amyloid precursor protein gene missense mutation (D678N) in probable familial Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004;75:1039-1042
127. Hendriks L, van Duijn CM, Cras P, et al. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene. Nat Genet 1992;1:218-221
128. Kamino K, Orr HT, Payami H, et al. Linkage and mutational analysis of familial Alzheimer disease kindreds for the APP gene region. Am J Hum Genet 1992;51:998-1014
129. Grabowski TJ, Cho HS, Vonsattel JP, et al. Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. Ann Neurol 2001;49:697-705
130. Armstrong J, Boada M, Rey MJ, et al. Familial Alzheimer disease associated with A713T mutation in APP. Neurosci Lett 2004;370:241-243
131. Rossi G, Giaccone G, Maletta R, et al. A family with Alzheimer disease and strokes associated with A713T mutation of the APP gene. Neurology 2004;63:910-912
132. Pasalar P, Najmabadi H, Noorian AR, et al. An Iranian family with Alzheimer's disease caused by a novel APP mutation (Thr714A1a). Neurology 2002;58:1574-1575
133. Kumar-Singh S, De JC, Cruts M, et al. Nonfibrillar diffuse amyloid deposition due to a gamma(42)-secretase site mutation points to an essential role for N-truncated A beta(42) in Alzheimer's disease. Hum Mol Genet 2000;9:2589-2598
134. Ancolio K, Dumanchin C, Barelli H, et al. Unusual phenotypic alteration of beta amyloid precursor protein (betaAPP) maturation by a new Val-715 -> Met betaAPP-770 mutation responsible for probable early-onset Alzheimer's disease. Proc Natl Acad Sci U S A 1999;96:4119-4124
135. De JC, Esselens C, Kumar-Singh S, et al. Pathogenic APP mutations near the gamma-secretase cleavage site differentially affect Abeta secretion and APP C-terminal fragment stability. Hum Mol Genet 2001;10:1665-1671
136. Eckman CB, Mehta ND, Crook R, et al. A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of A beta 42(43). Hum Mol Genet 1997;6:2087-2089
137. Murrell J, Farlow M, Ghetti B, et al. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science 1991;254:97-99
138. Chartier-Harlin MC, Crawford F, Houlden H, et al. Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature 1991;353:844-846
139. Murrell JR, Hake AM, Quaid KA, et al. Early-onset Alzheimer disease caused by a new mutation (V717L) in the amyloid precursor protein gene. Arch Neurol 2000;57:885-887
140. Kwok JB, Li QX, Hallupp M, et al. Novel Leu723Pro amyloid precursor protein mutation increases amyloid beta42(43) peptide levels and induces apoptosis. Ann Neurol 2000;47:249-253
141. Rogaeva EA, Fafel KC, Song YQ, et al. Screening for PS1 mutations in a referral-based series of AD cases: 21 novel mutations. Neurology 2001;57:621-625
142. Dumanchin C, Brice A, Campion D, et al. De novo presenilin 1 mutations are rare in clinically sporadic, early onset Alzheimer's disease cases. French Alzheimer's Disease Study Group. J Med Genet 1998;35:672-673
143. Cruts M, Van BC. Presenilin mutations in Alzheimer's disease. Hum Mutat 1998;11:183-190
144. Rossor MN, Fox NC, Beck J, et al. Incomplete penetrance of familial Alzheimer's disease in a pedigree with a novel presenilin-1 gene mutation [letter]. Lancet 1996;347:1560
145. Campion D, Flaman JM, Brice A, et al. Mutations of the presenilin I gene in families with early-onset Alzheimer's disease. Hum Mol Genet 1995;4:2373-2377
146. Cruts M, Backhovens H, Wang SY, et al. Molecular genetic analysis of familial early-onset Alzheimer's disease linked to chromosome 14q24.3. Hum Mol Genet 1995;4:2363-2371
147. Houlden H, Baker M, McGowan E, et al. Variant Alzheimer's disease with spastic paraparesis and cotton wool plaques is caused by PS-1 mutations that lead to exceptionally high amyloid-beta concentrations. Ann Neurol 2000;48:806-808
148. Sorbi S, Nacmias B, Forleo P, et al. Missense mutation of S182 gene in Italian families with early-onset Alzheimer's disease. Lancet 1995;346:439-440
149. Ataka S, Tomiyama T, Takuma H, et al. A novel presenilin-1 mutation (Leu85Pro) in early-onset Alzheimer disease with spastic paraparesis. Arch Neurol 2004;61:1773-1776
150. Queralt R, Ezquerra M, Lleo A, et al. A novel mutation (V89L) in the presenilin 1 gene in a family with early onset Alzheimer's disease and marked behavioural disturbances. J Neurol Neurosurg Psychiatry 2002;72:266-269
151. The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families. Alzheimer's Disease Collaborative Group. Nat Genet 1995;11:219-222
152. Tedde A, Nacmias B, Ciantelli M, et al. Identification of new presenilin gene mutations in early-onset familial Alzheimer disease. Arch Neurol 2003;60:1541-1544
153. Jorgensen P, Bus C, Pallisgaard N, et al. Familial Alzheimer's disease co-segregates with a Met146Ile substitution in presenilin-1. Clin Genet 1996;50:281-286
154. Arango D, Cruts M, Torres O, et al. Systematic genetic study of Alzheimer disease in Latin America: mutation frequencies of the amyloid beta precursor protein and presenilin genes in Colombia. Am J Med Genet 2001;103:138-143
155. Gustafson L, Brun A, Englund E, et al. A 50-year perspective of a family with chromosome-14-linked Alzheimer's disease. Hum Genet 1998;102:253-257
156. Kamino K, Sato S, Sakaki Y, et al. Three different mutations of presenilin 1 gene in early-onset Alzheimer's disease families. Neurosci Lett 1996;208:195-198
157. Finckh U, Muller-Thomsen T, Mann U, et al. High prevalence of pathogenic mutations in patients with early-onset dementia detected by sequence analyses of four different genes. Am J Hum Genet 2000;66:110-117
158. Campion D, Dumanchin C, Hannequin D, et al. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet 1999;65:664-670
159. Raux G, Gantier R, Thomas-Anterion C, et al. Dementia with prominent frontotemporal features associated with L113P presenilin 1 mutation. Neurology 2000;55:1577-1578
160. Raux G, Gantier R, Martin C, et al. A novel presenilin 1 missense mutation (L153V) segregating with early-onset autosomal dominant Alzheimer's disease. Hum Mutat 2000;16:95
161. Tysoe C, Whittaker J, Xuereb J, et al. A presenilin-1 truncating mutation is present in two cases with autopsy-confirmed early-onset Alzheimer disease. Am J Hum Genet 1998;62:70-76
162. Hattori S, Sakuma K, Wakutani Y, et al. A novel presenilin 1 mutation (Y154N) in a patient with early onset Alzheimer's disease with spastic paraparesis. Neurosci Lett 2004;368:319-322
163. Janssen JC, Beck JA, Campbell TA, et al. Early onset familial Alzheimer's disease: mutation frequency in 31 families. Neurology 2003;60:235-239
164. Romero I, Jorgensen P, Bolwig G, et al. Apresenilin-1 Thr116Asn substitution in a family with early-onset Alzheimer's disease. Neuroreport 1999;10:2255-2260
165. La B, V, Liguori M, Cittadella R, et al. A novel mutation (Thr116Ile) in the presenilin 1 gene in a patient with early-onset Alzheimer's disease. Eur J Neurol 2004;11:521-524
166. Wisniewski T, Dowjat WK, Buxbaum JD, et al. A novel Polish presenilin-1 mutation (P117L) is associated with familial Alzheimer's disease and leads to death as early as the age of 28 years. Neuroreport 1998;9:217-221
167. Dowjat WK, Kuchna I, Wisniewski T, et al. A novel highly pathogenic Alzheimer presenilin-1 mutation in codon 117 (Pro117Ser): comparison of clinical, neuropathological and cell culture phenotypes of Pro117Leu and Pro117Ser mutations. J Alzheimers Dis 2004;6:31-43
168. Ezquerra M, Carnero C, Blesa R, et al. A novel presenilin 1 mutation (Leu166Arg) associated with early-onset Alzheimer disease. Arch Neurol 2000;57:485-488
169. Zekanowski C, Styczynska M, Peplonska B, et al. Mutations in presenilin 1, presenilin 2 and amyloid precursor protein genes in patients with early-onset Alzheimer's disease in Poland. Exp Neurol 2003;184:991-996
170. Moehlmann T, Winkler E, Xia X, et al. Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Abeta 42 production. Proc Natl Acad Sci U S A 2002;99:8025-8030
171. Hutton M, Busfield F, Wragg M, et al. Complete analysis of the presenilin 1 gene in early onset Alzheimer's disease. Neuroreport 1996;7:801-805
172. Taddei K, Kwok JB, Kril JJ, et al. Two novel presenilin-1 mutations (Ser169Leu and Pro436Gln) associated with very early onset Alzheimer's disease. Neuroreport 1998;9:3335-3339
173. Poorkaj P, Sharma V, Anderson L, et al. Missense mutations in the chromosome 14 familial Alzheimer's disease presenilin 1 gene. Hum Mutat 1998;11:216-221
174. Yasuda M, Maeda K, Hashimoto M, et al. A pedigree with a novel presenilin 1 mutation at a residue that is not conserved in presenilin 2. Arch Neurol 1999;56:65-69
175. Ramirez-Duenas MG, Rogaeva EA, Leal CA, et al. A novel Leu171Pro mutation in presenilin-1 gene in a Mexican family with early onset Alzheimer disease. Ann Genet 1998;41:149-153
176. Crook R, Ellis R, Shanks M, et al. Early-onset Alzheimer's disease with a presenilin-1 mutation at the site corresponding to the Volga German presenilin-2 mutation. Ann Neurol 1997;42:124-128
177. Boteva K, Vitek M, Mitsuda H, et al. Mutation analysis of presenillin 1 gene in Alzheimer's disease [letter]. Lancet 1996;347:130-131
178. Bertoli Avella AM, Marcheco TB, Llibre Rodriguez JJ, et al. A novel presenilin 1 mutation (L174 M) in a large Cuban family with early onset Alzheimer disease. Neurogenetics 2002;4:97-104
179. Miklossy J, Taddei K, Suva D, et al. Two novel presenilin-1 mutations (Y256S and Q222H) are associated with early-onset Alzheimer's disease. Neurobiol Aging 2003;24:655-662
180. Dermaut B, Kumar-Singh S, Engelborghs S, et al. A novel presenilin 1 mutation associated with Pick's disease but not beta-amyloid plaques. Ann Neurol 2004;55:617-626
181. Rogaev EI, Sherrington R, Rogaeva EA, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 1995;376:775-778
182. Yasuda M, Maeda K, Ikejiri Y, et al. A novel missense mutation in the presenilin-1 gene in a familial Alzheimer's disease pedigree with abundant amyloid angiopathy. Neurosci Lett 1997;232:29-32
183. Forsell C, Froelich S, Axelman K, et al. A novel pathogenic mutation (Leu262Phe) found in the presenilin 1 gene in early-onset Alzheimer's disease. Neurosci Lett 1997;234:3-6
184. Wasco W, Pettingell WP, Jondro PD, et al. Familial Alzheimer's chromosome 14 mutations [letter]. Nat Med 1995;1:848
185. Goldman JS, Reed B, Gearhart R, et al. Very early-onset familial
186. Sugiyama N, Suzuki K, Matsumura T, et al. A novel missense mutation (G209R) in exon 8 of the presenilin 1 gene in a Japanese family with presenile familial Alzheimer's disease. Mutation in brief no. 254. Online. Hum Mutat 1999;14:90
187. Kowalska A, Pruchnik-Wolinska D, Florczak J, et al. Presenilin 1 mutations in Polish families with early-onset Alzheimer's disease. Folia Neuropathol 2004;42:9-14
188. Perez-Tur J, Croxton R, Wright K, et al. A further presenilin 1 mutation in the exon 8 cluster in familial Alzheimer's disease. Neurodegeneration 1996;5:207-212
189. Gomez-Isla T, Wasco W, Pettingell WP, et al. A novel presenilin-1 mutation: increased beta-amyloid and neurofibrillary changes. Ann Neurol 1997;41:809-813
190. Kwok JB, Halliday GM, Brooks WS, et al. Presenilin-1 mutation L271V results in altered exon 8 splicing and Alzheimer's disease with non-cored plaques and no neuritic dystrophy. J Biol Chem 2003;278:6748-6754
191. Takao M, Ghetti B, Hayakawa I, et al. A novel mutation (G217D) in the Presenilin 1 gene (PSEN1) in a Japanese family: presenile dementia and parkinsonism are associated with cotton wool plaques in the cortex and striatum. Acta Neuropathol (Berl) 2002;104:155-170
192. Jimenez-Escrig A, Rabano A, Guerrero C. et al. New V272A presenilin 1 mutation with very early onset subcortical dementia and parkinsonism. Eur J Neurol 2004;11:663-669
193. Smith MJ, Gardner RJ, Knight MA, et al. Early-onset Alzheimer's disease caused by a novel mutation at codon 219 of the presenilin-1 gene. Neuroreport 1999;10:503-507
194. Kamimura K, Tanahashi H, Yamanaka H, et al. Familial Alzheimer's disease genes in Japanese. J Neurol Sci 1998;160:76-81
195. Assini A, Terreni L, Borghi R, et al. Pure spastic paraparesis associated with a novel presenilin 1 R278K mutation. Neurology 2003;60:150
196. Coleman P, Kurlan R, Crook R, et al. A new presenilin Alzheimer's disease case confirms the helical alignment of pathogenic mutations in transmembrane domain 5. Neurosci Lett 2004;364:139-140
197. Godbolt AK, Beck JA, Collinge J, et al. A presenilin 1 R278I mutation presenting with language impairment. Neurology 2004;63:1702-1704
198. Kwok JB, Taddei K, Hallupp M, et al. Two novel (M233T and R278T) presenilin-1 mutations in early-onset Alzheimer's disease pedigrees and preliminary evidence for association of presenilin-1 mutations with a novel phenotype. Neuroreport 1997;8:1537-1542
199. Aldudo J, Bullido MJ, Arbizu T, et al. Identification of a novel mutation (Leu282Arg) of the human presenilin 1 gene in Alzheimer's disease. Neurosci Lett 1998;240:174-176
200. Aldudo J, Bullido MJ, Valdivieso F. DGGE method for the mutational analysis of the coding and proximal promoter regions of the Alzheimer's disease presenilin-1 gene: two novel mutations. Hum Mutat 1999;14:433-439
201. Dermaut B, Kumar-Singh S, De JC, et al. Cerebral amyloid angiopathy is a pathogenic lesion in Alzheimer's disease due to a novel presenilin 1 mutation. Brain 2001;124:2383-2392
202. Houlden H, Crook R, Dolan RJ, et al. A novel presenilin mutation (M233V) causing very early onset Alzheimer's disease with Lewy bodies. Neurosci Lett 2001;313:93-95
203. Tabira T, Chui de H, Nakayama H, et al. Alzheimer's disease with spastic paresis and cotton wool type plaques. J Neurosci Res 2002;70:367-372
204. Sodeyama N, Iwata T, Ishikawa K. et al. Very early onset Alzheimer's disease with spastic paraparesis associated with a novel presenilin 1 mutation (Phe237Ile). J Neurol Neurosurg Psychiatry 2001;71:556-557
205. Perez-Tur J, Froelich S, Prihar G, et al. A mutation in Alzheimer's disease destroying a splice acceptor site in the presenilin-1 gene. Neuroreport 1995;7:297-301
206. Crook R, Verkkoniemi A, Perez-Tur J, et al. A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nat Med 1998;4:452-455
207. Furuya H, Yasuda M, Terasawa KJ, et al. A novel mutation (L250V) in the presenilin 1 gene in a Japanese familial Alzheimer's disease with myoclonus and generalized convulsion. J Neurol Sci 2003;209:75-77
208. Besancon R, Lorenzi A, Cruts M, et al. Missense mutation in exon 11 (Codon 378) of the presenilin-1 gene in a French family with early-onset Alzheimer's disease and transmission study by mismatch enhanced allele specific amplification. Mutations in brief no. 141. Online. besancon@rockefeller1.univ. lyon1.fr. Hum Mutât 1998;11:481
209. Tedde A, Forleo P, Nacmias B, et al. A presenilin-1 mutation (Leu392Pro) in a familial AD kindred with psychiatric symptoms at onset. Neurology 2000;55:1590-1591
210. Yasuda M, Maeda S, Kawamata T, et al. Novel presenilin-1 mutation with widespread cortical amyloid deposition but limited cerebral amyloid angiopathy. J Neurol Neurosurg Psychiatry 2000;68:220-223
211. Kowalska A, Forsell C, Florczak J, et al. A Polish pedigree with Alzheimer's disease determined by a novel mutation in exon 12 of the presenilin 1 gene: clinical and molecular characterization. Folia Neuropathol 1999;37:57-61
212. Matsushita S, Arai H, Okamura N, et al. Clinical and biomarker investigation of a patient with a novel presenilin-1 mutation (A431V) in the mild cognitive impairment stage of Alzheimer's disease. Biol Psychiatry 2002;52:907-910
213. Devi G, Fotiou A, Jyrinji D, et al. Novel presenilin 1 mutations associated with early onset of dementia in a family with both early-onset and late-onset Alzheimer disease. Arch Neurol 2000;57:1454-1457
214. Palmer MS, Beck JA, Campbell TA, et al. Pathogenic presenilin 1 mutations (P436S & I143F) in early-onset Alzheimer's disease in the UK. Mutations in brief no. 223. Online. Hum Mutat 1999;13:256
215. Cruts M, van Duijn CM, Backhovens H, et al. Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease. Hum Mol Genet 1998;7:43-51
216. Lao JI, Beyer K, Fernandez-Novoa L, et al. A novel mutation in the predicted TM2 domain of the presenilin 2 gene in a Spanish patient with late-onset Alzheimer's disease. Neurogenetics 1998;1:293-296
217. Lleo A, Blesa R, Queralt R, et al. Frequency of mutations in the presenilin and amyloid precursor protein genes in early-onset Alzheimer disease in Spain. Arch Neurol 2002;59:1759-1763
218. Tsuji T, Shiozaki A, Kohno R, et al. Proteomic profiling and neurodegeneration in Alzheimer's disease. Neurochem Res 2002;27:1245-1253
219. Schuller E, Gulesserian T, Seidl R, et al. Brain t-complex polypeptide 1 (TCP-1) related to its natural substrate beta1 tubulin is decreased in Alzheimer's disease. Life Sci 2001;69:263-270
220. Kim SH, Lubec G. Brain alpha-endosulfine is manifold decreased in brains from patients with Alzheimer's disease: a tentative marker and drug target? Neurosci Lett 2001;310:77-80
221. Kim SH, Nairn AC, Cairns N, et al. Decreased levels of ARPP-19 and PKA in brains of Down syndrome and Alzheimer's disease. J Neural Transm Suppl 2001;61:263-272
222. Kim SH, Cairns N, Fountoulakisc M, et al. Decreased brain histamine-releasing factor protein in patients with Down syndrome and Alzheimer's disease. Neurosci Lett 2001;300:41-44
223. Krapfenbauer K, Yoo BC, Fountoulakis M, et al. Expression patterns of antioxidant proteins in brains of patients with sporadic Creutzfeldt-Jacob disease. Electrophoresis 2002;23:2541-2547
224. Aksenov M, Aksenova M, Butterfield DA, et al. Oxidative modification of creatine kinase BB in Alzheimer's disease brain. J Neurochem 2000;74:2520-2527
225. Castegna A, Thongboonkerd V, Klein JB, et al. Proteomic identification of nitrated proteins in Alzheimer's disease brain. J Neurochem 2003;85:1394-1401
226. Kim SH, Vlkolinsky R, Cairns N, et al. The reduction of NADH ubiquinone oxidoreductase 24- and 75-kDa subunits in brains of patients with Down syndrome and Alzheimer's disease. Life Sci 2001;68:2741-2750
227. Kim SH, Vlkolinsky R, Cairns N, et al. Decreased levels of complex III core protein 1 and complex V beta chain in brains from patients with Alzheimer's disease and Down syndrome. Cell Mol Life Sci 2000;57:1810-1816
228. Yoo BC, Fountoulakis M, Cairns N, et al. Changes of voltage-dependent anion-selective channel proteins VDAC1 and VDAC2 brain levels in patients with Alzheimer's disease and Down syndrome. Electrophoresis 2001;22:172-179
229. Engidawork E, Gulesserian T, Yoo BC, et al. Alteration of caspases and apoptosis-related proteins in brains of patients with Alzheimer's disease. Biochem Biophys Res Commun 2001;281:84-93
230. Shim KS, Lubec G. Drebrin, a dendritic spine protein, is manifold decreased in brains of patients with Alzheimer's disease and Down syndrome. Neurosci Lett 2002;324:209-212
231. Bajo M, Yoo BC, Cairns N, et al. Neurofilament proteins NF-L, NF-M and NF-H in brain of patients with Down syndrome and Alzheimer's disease. Amino Acids 2001;21:293-301
232. Puchades M, Hansson SF, Nilsson CL, et al. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res Mol Brain Res 2003;118:140-146
233. Davidsson P, Westman-Brinkmalm A, Nilsson CL, et al. Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. Neuroreport 2002;13:611-615